AstraZeneca’s COVID-19 vaccine: European Medicines Agency to provide further context on risk of very rare blood clots with low blood platelets

The review by CHMP will enable authorities to put the risks of the vaccine into the context of the benefits of ongoing vaccination campaigns. It will also consider whether to update recommendations for a second dose in those who have already received the first dose.

Source:

European Medicines Agency